Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer
Commercial Sponsor
Merck
Summary
Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200mg pembrolizumab and 200mg vibostolimab (also known as MK7684A) every 3 weeks, in combination with 100mg/m^2 etoposide, and platinum chemotherapy (Area Under the Curve [AUC] 5 mg/mL/min carboplatin or 75mg/m^2 cisplatin)every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of MK7684A every 3 weeks. In the Active Comparator Arm, participants will receive 4 cycles (each cycle is 3 weeks) of 1200mg atezolizumab every 3 weeks, in combination with 100mg/m^2 etoposide and platinum chemotherapy (AUC 5mg/mL/min carboplatin or 75mg/m^2 cisplatin) every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of atezolizumab every 3 weeks.